Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie Sells 689 Shares of Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 689 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.26, for a total transaction of $12,581.14. Following the completion of the sale, the chief operating officer now directly owns 336,136 shares of the company’s stock, valued at approximately $6,137,843.36. This trade represents a 0.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Fulgent Genetics Stock Performance

Shares of FLGT opened at $18.07 on Thursday. The company has a 50 day moving average price of $19.96 and a 200-day moving average price of $21.16. Fulgent Genetics, Inc. has a fifty-two week low of $16.56 and a fifty-two week high of $30.68. The stock has a market capitalization of $552.76 million, a PE ratio of -3.27 and a beta of 1.51.

Institutional Investors Weigh In On Fulgent Genetics

Several hedge funds have recently modified their holdings of FLGT. State Board of Administration of Florida Retirement System purchased a new stake in shares of Fulgent Genetics in the 1st quarter worth approximately $178,000. Vanguard Group Inc. lifted its position in shares of Fulgent Genetics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,424,448 shares of the company’s stock worth $30,911,000 after purchasing an additional 8,257 shares during the period. CANADA LIFE ASSURANCE Co lifted its position in shares of Fulgent Genetics by 11.0% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 29,103 shares of the company’s stock worth $631,000 after purchasing an additional 2,879 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Fulgent Genetics by 32.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,261 shares of the company’s stock worth $310,000 after purchasing an additional 3,458 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Fulgent Genetics by 36.4% in the 2nd quarter. SG Americas Securities LLC now owns 12,826 shares of the company’s stock worth $252,000 after purchasing an additional 3,425 shares during the period. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on FLGT. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday. Piper Sandler lowered their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Monday, November 11th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.